Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Free testosterone and cardiometabolic parameters in men: comparison of algorithms

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{d98d22537b974251b3a5fc2d90337e12,
title = "Free testosterone and cardiometabolic parameters in men: comparison of algorithms",
abstract = "OBJECTIVE: Calculating the free testosterone level has gained increasing interest and different indirect algorithms have been suggested. The objective was to compare free androgen index (FAI), free testosterone estimated using the linear binding model (Vermeulen: cFTV) and the binding framework accounting for allosterically coupled SHBG monomers (Zakharov: cFTZ) in relation to cardiometabolic conditions.DESIGN: A prospective cohort study including 5,350 men, aged 30-70 years, participating in population-based surveys (MONICA I-III and Inter99) from 1982-2001 and followed until December 2012 with baseline and follow-up information on cardiometabolic parameters and vital status.RESULTS: Using age-standardized hormone levels, FAI was higher among men with baseline cardiometabolic conditions, whereas cFTV and cFTZ levels were lower compared to men without these conditions as also seen for total testosterone. Men in highest quartiles of cFTV or cFTZ had lower risk of developing type 2 diabetes (cFTV: HR=0.74 (0.49-1.10), cFTZ: HR=0.59 (0.39-0.91)) than men in lowest quartile. In contrast, men with highest levels of FAI had a 74% (1.17-2.59) increased risk of developing type 2 diabetes compared to men in lowest quartile.CONCLUSION: The association of estimated free testosterone and the studied outcomes differ depending on algorithm used. cFTV and cFTZ showed similar associations to baseline and long-term cardiometabolic parameters. In contrast, an empiric ratio, FAI, showed opposite associations to several of the examined parameters and may reflect limited clinical utility.",
author = "{A Holmboe}, Stine and Ravi Jasuja and Brian Lawney and L{\ae}rke Priskorn and Niels Joergensen and Allan Linneberg and Jensen, {Tina Kold} and Skakkeb{\ae}k, {Niels Erik} and Anders Juul and Anna-Maria Andersson",
year = "2021",
month = feb,
doi = "10.1530/EC-20-0552",
language = "English",
volume = "10",
pages = "220--229",
journal = "Endocrine Connections",
issn = "2049-3614",
publisher = "BioScientifica Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Free testosterone and cardiometabolic parameters in men

T2 - comparison of algorithms

AU - A Holmboe, Stine

AU - Jasuja, Ravi

AU - Lawney, Brian

AU - Priskorn, Lærke

AU - Joergensen, Niels

AU - Linneberg, Allan

AU - Jensen, Tina Kold

AU - Skakkebæk, Niels Erik

AU - Juul, Anders

AU - Andersson, Anna-Maria

PY - 2021/2

Y1 - 2021/2

N2 - OBJECTIVE: Calculating the free testosterone level has gained increasing interest and different indirect algorithms have been suggested. The objective was to compare free androgen index (FAI), free testosterone estimated using the linear binding model (Vermeulen: cFTV) and the binding framework accounting for allosterically coupled SHBG monomers (Zakharov: cFTZ) in relation to cardiometabolic conditions.DESIGN: A prospective cohort study including 5,350 men, aged 30-70 years, participating in population-based surveys (MONICA I-III and Inter99) from 1982-2001 and followed until December 2012 with baseline and follow-up information on cardiometabolic parameters and vital status.RESULTS: Using age-standardized hormone levels, FAI was higher among men with baseline cardiometabolic conditions, whereas cFTV and cFTZ levels were lower compared to men without these conditions as also seen for total testosterone. Men in highest quartiles of cFTV or cFTZ had lower risk of developing type 2 diabetes (cFTV: HR=0.74 (0.49-1.10), cFTZ: HR=0.59 (0.39-0.91)) than men in lowest quartile. In contrast, men with highest levels of FAI had a 74% (1.17-2.59) increased risk of developing type 2 diabetes compared to men in lowest quartile.CONCLUSION: The association of estimated free testosterone and the studied outcomes differ depending on algorithm used. cFTV and cFTZ showed similar associations to baseline and long-term cardiometabolic parameters. In contrast, an empiric ratio, FAI, showed opposite associations to several of the examined parameters and may reflect limited clinical utility.

AB - OBJECTIVE: Calculating the free testosterone level has gained increasing interest and different indirect algorithms have been suggested. The objective was to compare free androgen index (FAI), free testosterone estimated using the linear binding model (Vermeulen: cFTV) and the binding framework accounting for allosterically coupled SHBG monomers (Zakharov: cFTZ) in relation to cardiometabolic conditions.DESIGN: A prospective cohort study including 5,350 men, aged 30-70 years, participating in population-based surveys (MONICA I-III and Inter99) from 1982-2001 and followed until December 2012 with baseline and follow-up information on cardiometabolic parameters and vital status.RESULTS: Using age-standardized hormone levels, FAI was higher among men with baseline cardiometabolic conditions, whereas cFTV and cFTZ levels were lower compared to men without these conditions as also seen for total testosterone. Men in highest quartiles of cFTV or cFTZ had lower risk of developing type 2 diabetes (cFTV: HR=0.74 (0.49-1.10), cFTZ: HR=0.59 (0.39-0.91)) than men in lowest quartile. In contrast, men with highest levels of FAI had a 74% (1.17-2.59) increased risk of developing type 2 diabetes compared to men in lowest quartile.CONCLUSION: The association of estimated free testosterone and the studied outcomes differ depending on algorithm used. cFTV and cFTZ showed similar associations to baseline and long-term cardiometabolic parameters. In contrast, an empiric ratio, FAI, showed opposite associations to several of the examined parameters and may reflect limited clinical utility.

U2 - 10.1530/EC-20-0552

DO - 10.1530/EC-20-0552

M3 - Journal article

C2 - 33544092

VL - 10

SP - 220

EP - 229

JO - Endocrine Connections

JF - Endocrine Connections

SN - 2049-3614

IS - 2

ER -

ID: 63789382